<DOC>
	<DOCNO>NCT02603081</DOCNO>
	<brief_summary>This study evaluate safety efficacy three dose level SPI-1005 compare placebo vertigo , tinnitus sensorineural hearing loss 40 adult Meniere 's disease .</brief_summary>
	<brief_title>Study Evaluate SPI-1005 Adults With Meniere 's Disease</brief_title>
	<detailed_description>Randomized , double-blind , placebo-controlled safety , pharmacokinetic , pharmacodynamic study oral SPI-1005 adult Meniere 's disease . All subject undergo baseline audiometric test severity sensorineural hearing loss , tinnitus vertigo determine start 21-day course treatment SPI-1005 placebo . During treatment SPI-1005 , 7 day 28 day follow cessation SPI-1005 , subject hearing loss , tinnitus vertigo assess . Additional test include electrocochleography perform baseline , end SPI-1005 treatment , 28 day SPI-1005 treatment stop . Six outpatient visit perform 7-week period .</detailed_description>
	<mesh_term>Meniere Disease</mesh_term>
	<mesh_term>Ebselen</mesh_term>
	<criteria>Diagnosis probable definite Meniere 's Disease AAOHNS 1995 criterion within 12 month study enrollment ; Voluntarily consent participate study ; Females childbearing potential use committed continue use one follow acceptable birth control method : Sexual abstinence ( inactivity ) 14 day prior screen study completion ; IUD place least 3 month prior study study completion ; Barrier method ( condom diaphragm ) spermicide least 14 day prior screen study completion ; Stable hormonal contraceptive least 3 month prior study study completion ; Surgical sterilization ( vasectomy ) partner least 6 month prior study . Females nonchildbearing potential surgically sterile ( bilateral tubal ligation surgery least 6 month prior study , hysterectomy , bilateral oophorectomy least 2 month prior study ) least 3 year since last menses . Current use within 90 day prior study ototoxic medication aminoglycoside antibiotic ( gentamicin , tobramycin , amikacin , streptomycin ) ; platinumcontaining chemotherapy ( cisplatin , carboplatin , oxaliplatin ) ; loop diuretic ( furosemide ) ; History idiopathic sensorineural hearing loss , otosclerosis , vestibular schwannoma ; History middle ear inner ear surgery ; Current conductive hearing loss middle ear effusion ; Significant cardiovascular , pulmonary , hepatic , renal , hematologic , gastrointestinal , endocrine , immunologic , psychiatric disease ; History hypersensitivity idiosyncratic reaction compound related ebselen ; Current use within 30 day prior study drug substance know strong inhibitor inducer cytochrome P450 enzyme ; Participation another investigational drug device study within 90 day prior study enrollment ; Female patient pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Meniere 's</keyword>
	<keyword>hearing loss</keyword>
	<keyword>vertigo</keyword>
	<keyword>tinnitus</keyword>
	<keyword>ebselen</keyword>
</DOC>